Who are prednisone and cyclophosphamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prednisolone plus Cyclophosphamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prednisone-and-cyclophosphamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

prednisone and cyclophosphamide — Competitive Intelligence Brief

prednisone and cyclophosphamide (prednisone and cyclophosphamide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Alkylating agent combination. Area: Immunology / Oncology.

marketed Corticosteroid + Alkylating agent combination Immunology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

prednisone and cyclophosphamide (prednisone and cyclophosphamide) — Guangdong Provincial People's Hospital. Prednisone suppresses immune and inflammatory responses while cyclophosphamide acts as an alkylating agent to kill rapidly dividing cells, together providing immunosuppression and cytotoxic effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
prednisone and cyclophosphamide TARGET	prednisone and cyclophosphamide	Guangdong Provincial People's Hospital	marketed	Corticosteroid + Alkylating agent combination
Prednisolone plus Cyclophosphamide	Prednisolone plus Cyclophosphamide	Air Force Military Medical University, China	phase 3	Corticosteroid + Alkylating agent combination	Glucocorticoid receptor (prednisolone); DNA (cyclophosphamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Alkylating agent combination class)

Air Force Military Medical University, China · 1 drug in this class
Guangdong Provincial People's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). prednisone and cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/prednisone-and-cyclophosphamide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab